Almirall, S.A. (LBTSF)

Market Cap	2.93B +24.1%
Revenue (ttm)	1.29B +9.0%
Net Income	45.95M +63.7%
EPS	n/a
Shares Out	n/a
PE Ratio	63.79
Forward PE	28.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	812
Open	15.35
Previous Close	15.47
Day's Range	15.35 - 15.35
52-Week Range	9.01 - 15.47
Beta	0.19
RSI	65.04
Earnings Date	May 11, 2026

About Almirall

Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism, anti-infective for systemic use, cardiovascular system, dermatological, genito urinary system and sex hormones, immunostimulants, metabolism, musculo-skeletal sys...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1943
• Employees: 2,108
• Stock Exchange: OTCMKTS
• Ticker Symbol: LBTSF

Financial Performance

In 2025, Almirall's revenue was 1.11 billion, an increase of 12.51% compared to the previous year's 990.63 million. Earnings were 46.15 million, an increase of 354.85%.

Financial numbers in EUR